UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Browse by UCL Departments and Centres

Up a level
Export as [feed] RSS 2.0 [feed] RSS 1.0 [feed] Atom
Group by: Author | Type
Jump to: A | B | C | D | E | F | G | H | J | K | L | M | N | O | P | R | S | T | U | V | W | Z
Number of items: 140.

A

Alley, MC; Hollingshead, MG; Pacula-Cox, CM; Waud, WR; Hartley, JA; Howard, PW; ... Sausville, EA; + view all (2002) Efficacy evaluations of SJG-136 (NSC 694501), a novel pyrrolobenzodiazepine dimer with broad spectrum antitumor activity. In: Proc Am Assoc Cancer Res. (pp. 315 - ?).

Arcaro, A; Khanzada, UK; Vanhaesebroeck, B; Tetley, TD; Waterfield, MD; Seckl, MJ; (2002) Two distinct phosphoinositide 3-kinases mediate polypeptide growth factor-stimulated PKB activation. EMBO J , 21 (19) 5097 - 5108.

Ardeshna, K; Smith, P; Norton, A; Hancock, B; Hoskin, PJ; (2002) The long term impact of a watch and wait policy vs immediate systemic treatment for asymptomatic advanced stage indolent non Hodgkin's lymphoma: results of a British National Lymphoma randomized trial. In: Annals Of Oncology. (pp. 76 - ?).

Arkenau, H-T; Widjaja, A; (2002) Ein seltener fall von cholestase und makrohämaturie bei einem 52-jährigen patienen. Medizinische Klinik , 97 (8) 480 - 483. 10.1007/s00063-002-1183-3.

Arkenau, HT; Stichtenoth, DO; Frölich, JC; Manns, MP; Böker, KH; (2002) Elevated nitric oxide levels in patients with chronic liver disease and cirrhosis correlate with disease stage and parameters of hyperdynamic circulation. Z Gastroenterol , 40 (11) 907 - 913. 10.1055/s-2002-35413.

Arkenau, HT; Widjaja, A; (2002) [A rare case of cholestasis and macrohematuria in a 52-year-old patient]. Med Klin (Munich) , 97 (8) 480 - 483.

Atalay, G; Biganzoli, L; Renard, F; Paridaens, R; Batter, V; Coleman, R; ... Cofer, T; + view all (2002) Clinical outcome of breast cancer patients with liver metastases in the anthracycline-taxane era. Breast Cancer Research and Treatment , 76 138 - ?.

B

Baraldi, PG; Romagnoli, R; Guadix, AE; de las Infantas, MJP; Gallo, MA; Espinosa, A; ... Hartley, JA; + view all (2002) Design, synthesis, and biological activity of hybrid compounds between uramustine and DNA minor groove binder distamycin A. J MED CHEM , 45 (17) 3630 - 3638. 10.1021/jm011113b.

Baraldi, PG; Romagnoli, R; Pavani, MG; Nunez, MD; Bingham, JP; Hartley, JA; (2002) Benzoyl and cinnamoyl nitrogen mustard derivatives of benzoheterocyclic analogues of the tallimustine: Synthesis and antitumour activity. BIOORGAN MED CHEM , 10 (5) 1611 - 1618.

Baselga, J; Rischin, D; Ranson, M; Calvert, H; Raymond, E; Kieback, DG; ... Albanell, J; + view all (2002) Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J CLIN ONCOL , 20 (21) 4292 - 4302. 10.1200/JCO.2002.03.100.

Batey, MA; Wright, JG; Azzabi, A; Newell, DR; Lind, MJ; Calvert, AH; Boddy, AV; (2002) Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF). EUR J CANCER , 38 (8) 1081 - 1089.

Beauregard, DA; Pedley, RB; Hill, SA; Brindle, KM; (2002) Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS. NMR BIOMED , 15 (2) 99 - 105. 10.1002/nbm.723.

Bentzen, SM; Saunders, MI; Dische, S; (2002) From CHART to CHARTWEL in non-small cell lung cancer: Clinical radiobiological modelling of the expected change in outcome. Clinical Oncology , 14 (5) 372 - 381.

Biganzoli, L; Cufer, T; Bruning, P; Coleman, R; Duchateau, L; Calvert, AH; ... Piccart, MJ; + view all (2002) Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial. J CLIN ONCOL , 20 (14) 3114 - 3121. 10.1200/JCO.2002.11.005.

Boddy, AV; Todd, R; Verrill, M; Sludden, J; Fishwick, K; Robson, L; ... Calvert, AH; + view all (2002) Pharmacological study of CT-2103 (XyotaxTM), a poly(L-glutamic acid)-paclitaxel conjugate administered every 3 weeks or every 2 weeks in a phase I study. European Journal of Cancer , 38 98 - ?.

Bomanji, JB; Syed, R; Brock, C; Jankowska, P; Dogan, A; Costa, DC; ... Lee, SM; + view all (2002) Challenging cases and diagnostic dilemmas: case 2. Pitfalls of positron emission tomography for assessing residual mediastinal mass after chemotherapy for Hodgkin's disease. J Clin Oncol , 20 (15) 3347 - 3349.

Bowen, RL; Francis, RJ; Green, AJ; Baig, S; Knell, V; Buscombe, JR; ... Begent, RHJ; + view all (2002) How accurately can the oncologist report FDG-PET tumour response using the ADAC vertex plus dual-headed gamma camera? BRIT J CANCER , 86 S102 - S102.

Braybrooke, JP; Slade, A; Gibson, R; Deplanque, G; Madhusudan, S; Makris, A; (2002) Phase one study of MetXia-P450 gene therapy for patients with advanced breast cancer or melanoma. In: Proceedings ASCO. (pp. 22a - ?).

Brett, BT; Smith, SC; Bouvier, CV; Michaeli, D; Hochhauser, D; Davidson, BR; ... Caplin, ME; + view all (2002) Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J CLIN ONCOL , 20 (20) 4225 - 4231. 10.1200/JCO.2002.11.151.

Brock, CS; Lee, SM; (2002) Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer. Eur Respir J , 19 (3) 557 - 570.

Budhram-Mahadeo, V; Morris, P; Ndisang, D; Irshad, S; Lozano, G; Pedley, B; Latchman, DS; (2002) The Brn-3a POU family transcription factor stimulates p53 gene expression in human and mouse tumour cells. NEUROSCI LETT , 334 (1) 1 - 4.

Bunn, PA; Calvert, H; (2002) Pemetrexed, a novel multitargeted antifolate: Current development and future directions - Introduction. SEMIN ONCOL , 29 (2) 1 - 2. 10.1053/sonc.2002.30757.

Burcombe, RJ; Makris, A; Pittam, M; Lowe, J; Emmott, J; Wong, WL; (2002) Evaluation of good clinical response to neoadjuvant chemotherapy in primary breast cancer using [F-18]- fluorodeoxyglucose positron emission tomography. European Journal of Cancer , 38 (3) 375 - 379.

Burcombe, RJ; Makris, A; Wilson, GD; (2002) Evaluation of topoisomerase II-alpha as a predictor of clinical and pathological response to neoadjuvant chemotherapy in operable breast cancer. In: Proceedings ASCO. (pp. 447a - ?).

Burger, AM; Fiebig, HH; Hagan, DR; Tiberghien, A; Howard, PW; Schultz, R; ... Thurston, DE; + view all (2002) The monomer pyrrolobenzodiazepine (PBD) DNA minor-groove binding agent DRH-417 (NSC 709119) shows pre-clinical activity in human renal cell carcinoma. In: Proceedings of the American Association of Cancer Research. (pp. 5719 - ?).

C

Calvert, AH; Egorin, MJ; (2002) Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologies. EUR J CANCER , 38 (1) 11 - 16.

Calvert, H; (2002) Folate status and the safety profile of antifolates. SEMINARS IN ONCOLOGY , 29 (2) 3 - 7. 10.1053/sonc.2002.30761.

Calvert, H; Bunn, PA; (2002) Future directions in the development of pemetrexed. SEMINARS IN ONCOLOGY , 29 (2) 54 - 61. 10.1053/sonc.2002.30761.

Calvert, H; Jodrell, DI; Cassidy, J; Harris, AL; (2002) Efficacy, safety, and cost of new anticancer drugs - Pessimistic conclusion was not justified. BRIT MED J , 325 (7375) 1302 - 1303.

Casey, JL; Napier, MP; King, DJ; Pedley, RB; Chaplin, LC; Weir, N; ... Begent, RH; + view all (2002) Tumour targeting of humanised cross-linked divalent-Fab' antibody fragments: a clinical phase I/II study. Br J Cancer , 86 (9) 1401 - 1410. 10.1038/sj.bjc.6600198.

Casey, JL; Napier, MP; King, DJ; Pedley, RB; Chaplin, LC; Weir, N; ... Begent, RHJ; + view all (2002) Tumour targeting of humanised cross-linked divalent-fab ' antibody fragments: a clinical phase I/II study. BRIT J CANCER , 86 (9) 1401 - 1410. 10.1038/sj/bjc/6600198.

Chow, E; Coia, L; Wu, J; Nanjan, N; Kirkbride, P; Hoskin, PJ; (2002) Debate: this house believes that multiple-fraction radiotherapy is a barrier to referral for palliative radiotherapy for bone metastases. Current Oncology , 9 60 - 66.

Chow, E; Wu, JSY; Hoskin, P; Coia, LR; Bentzen, SM; Blitzer, PH; (2002) International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiotherapy And Oncology , 64 (3) 275 - 280.

Chow, E; Wu, JSY; Hoskin, P; Coia, LR; Bentzen, SM; Blitzer, PH; (2002) International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. International Journal of Cancer 7 - 7.

Cooke, SP; Pedley, RB; Boden, R; Begent, RH; Chester, KA; (2002) In vivo tumor delivery of a recombinant single chain Fv::tumor necrosis factor-alpha fusion [correction of factor: a fusion] protein. Bioconjug Chem , 13 (1) 7 - 15.

Cooke, SP; Pedley, RB; Boden, R; Begent, RHJ; Chester, KA; (2002) In vivo tumor delivery of a recombinant single chain fv :: tumor necrosis factor-alpha fusion protein (vol 13, pg 7, 2002). BIOCONJUGATE CHEM , 13 (2) 385 - 385. 10.1021/bc020015h.

Cooke, SP; Pedley, RB; Boden, R; Begent, RHJ; Chester, KA; (2002) In vivo tumor delivery of a recombinant single-chain Fv::Tumor necrosis factor: A fusion protein. Bioconjugate Chemistry , 13 (1) 7 - 15.

Cooke, SP; Pedley, RB; Boden, R; Begent, RHJ; Chester, KA; (2002) In vivo tumor delivery of a recombinant single-chain Fv::Tumor necrosis factor: A fusion protein. BIOCONJUGATE CHEM , 13 (1) 7 - 15. 10.1021/bc000178a.

Craddock, C; Hochhauser, D; (2002) Realising the potential of targeted therapies in oncology. LANCET , 360 (9331) 424 - 425.

D

De Silva, IU; McHugh, PJ; Clingen, PH; Hartley, JA; (2002) Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin. NUCLEIC ACIDS RES , 30 (17) 3848 - 3856. Gold open access

E

El-Emir, E; Petrie,; I, A; Boxer,; G, M; Boden,; ... R, HJAPRB; + view all (2002) Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice. In: (Proceedings) Proceedings BACR, Br J Cancer. (pp. 257 - ?).

El-Emir, E; Petrie, IA; Boxer, GM; Boden, R; Dearling, JLJ; Raleigh, JA; ... Pedley, RB; + view all (2002) Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice. BRIT J CANCER , 86 S112 - S112.

F

Flynn, AA; Green, AJ; Pedley, RB; Boxer, GM; Dearling, J; Watson, R; ... Begent, RH; + view all (2002) A model-based approach for the optimization of radioimmunotherapy through antibody design and radionuclide selection. Cancer , 94 (4 Suppl) 1249 - 1257.

Flynn, AA; Green, AJ; Pedley, RB; Boxer, GM; Dearling, J; Watson, R; ... Begent, RHJ; + view all (2002) A model-based approach for the optimization of radioimmunotherapy through antibody design and radionuclide selection. In: CANCER. (pp. 1249 - 1257). JOHN WILEY & SONS INC

Flynn, AA; Green, AJ; Pedley, RB; Boxer, GM; Dearling, J; Watson, R; ... R, HJ; + view all (2002) . A model-based approach for the optimization of radioimmunotherapy through antibody design and radionuclide selection. Cancer , 94 1249 - 1257.

Flynn, AA; Pedley, RB; Green, AJ; Boxer, GM; Boden, R; Bhatia, J; ... Begent, RHJ; + view all (2002) Antibody and radionuclide characteristics and the enhancement of the effectiveness of radioimmunotherapy by selective dose delivery to radiosensitive areas of tumour. International Journal of Radiation Biology , 78 (5) 407 - 415.

Flynn, AA; Pedley, RB; Green, AJ; Boxer, GM; Boden, R; Bhatia, J; ... Begent, RHJ; + view all (2002) Antibody and radionuclide characteristics and the enhancement of the effectiveness of radioimmunotherapy by selective dose delivery to radiosensitive areas of tumour. INT J RADIAT BIOL , 78 (5) 407 - 415. 10.1080/09553000110117818.

Flynn, AA; Pedley, RB; Green, AJ; Boxer, GM; Dearling, J; Boden, RABRHJ; (2002) Antibody and radionuclide characteristics can enhance the effectiveness of radioimmunotherapy by selective dose delivery to radiosensitive areas of tumour. International Journal of Radiation Biology , 78 407 - 415.

Ford, HER; Mitchell, F; Cunningham, D; Farrugia, DC; Hill, ME; Rees, C; ... Jackman, AL; + view all (2002) Patterns of elevation of plasma 2 '-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331. CLIN CANCER RES , 8 (1) 103 - 109.

Francis, RJ; Green, AJ; Baig, S; Knell, V; Frisken, I; Bowen, RL; ... Begent, RHJ; + view all (2002) A novel approach to assessing response to chemotherapy using hybrid camera FDG PET. BRIT J CANCER , 86 S100 - S100.

Francis, RJ; Sharma, SK; Springer, C; Green, AJ; Hope-Stone, LD; Sena, L; ... Begent, RHJ; + view all (2002) A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. BRIT J CANCER , 87 (6) 600 - 607. 10.1038/sj.bjc.6600517.

G

Gore, M; Oza, A; Rustin, G; Malfetano, J; Calvert, H; Clarke-Pearson, D; ... Fields, SZ; + view all (2002) A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. EUR J CANCER , 38 (1) 57 - 63.

Grimaldi, KA; McGurk, CJ; McHugh, PJ; Hartley, JA; (2002) PCR-based methods for detecting DNA damage and its repair at the sub-gene and single nucleotide levels in cells. MOL BIOTECHNOL , 20 (2) 181 - 196.

Gupta, N; Saleem, A; Osman, S; Hoskin, P; Price, PM; Aboagye, EO; (2002) Carbogen and nicotinamide selectively increase chemotherapy delivery and blood flow to liver metastasis. British Journal of Cancer , 86 S14 - S14.

H

Harney, J; Goodchild, K; Glynne-Jones, R; Phillips, H; Hoskin, PJ; Saunders, MI; (2002) A Phase I/II Study of CHARTWEL with concurrent chemotherapy in locally advanced inoperable carcinoma of the oesphagus. In: Radiotherapy And Oncology. (pp. S27 - ?).

Harney, J; Goodchild, K; Glynne-Jones, R; Phillips, H; Hoskin, PJ; Saunders, MI; (2002) A phase II study of CHARTWEL with concurrent chemotherapy in locally advanced, inoperable carcinoma of the oesophagus. In: Radiotherapy And Oncology. (pp. 83 - ?).

Harney, J; Shah, N; Joiner, M; Short, S; Saunders, MI; (2002) Low dose hyper-sensitivity- does it occur in normal skin? In: Proc 21st Annual ESTRO meeting, Prague 2002.

Harney, J; Shah, N; Short, SC; Joiner, M; Saunders, MI; (2002) Low dose hyper-radiosensitivity - does it exist in normal skin? In: Radiotherapy And Oncology. (pp. S57 - ?).

Harney, J; Short, SC; Saunders, MI; (2002) Low dose hyper-radiosensitivity - A clinical assessment. In: British Journal of Cancer. (pp. S56 - ?).

Hartley, JA; Spanswick, VJ; Pedley, RB; Hollingshead, MG; Alley, MC; Schultz, R; ... Thurston, DE; + view all (2002) In vitro antitumor activity and in vivo DNA interstrand crosslinking by the novel pyrrolobenzodiazepine dimer SJG-136 (NSC 694501). In: Proceedings of the American Association of Cancer Research. (pp. 2432 - ?).

Hartley, JA; Spanswick, VJ; Pedley, RB; Hollingshead, MG; Alley, MC; Schultz, R; ... D, E; + view all (2002) In vitro activity and in vivo DNA interstrand crosslinking by the novel pyrrolobenzodiazepine dimer SJG-136 (NSC 694501). In: (Proceedings) Proceedings American Association for Cancer Research. (pp. 489 - ?).

Hoskin, P; (2002) Secondary malignancies after radiotherapy. The Lancet Oncology , 3 (9) 577 - 578.

Hoskin, PJ; (2002) Conformal radiotherapy to the prostate: are bigger fields better? Clinical Oncology , 14 (4) 296 - 297.

Hoskin, PJ; (2002) FDG PET in the management of lymphoma: a clinical perspective. European Journal of Nuclear Medicine and Molecular Imaging , 29 (4) 449 - 451.

Hoskin, PJ; (2002) Tumour hypoxia and vascularity in lymphoma. In: Annals Of Oncology. (pp. 615 - ?).

Hoskin, PJ; (2002) Radiotherapy in cancer pain management. In: Rice, ASC and Warfield, CA and Justins, D and Eccleston, C and Arnold, E, (eds.) Clinical Pain Management. (253 - 258). : London.

Hoskin, PJ; (2002) Radiotherapy in palliative care. In: Rice, ASC and Warfield, CA and Justins, D and Eccleston, C and Arnold, E, (eds.) Clinical Pain Management. (281 - 292). Arnold: London.

Hoskin, PJ; Bownes, P; Summers, A; (2002) The influence of applicator angle on dosimetry in vaginal vault brachytherapy. British Journal of Radiology , 75 (891) 234 - 237.

Hoskin, PJ; Grover, A; Bhana, R; (2002) Optimal radiotherapy dose for metastatic spinal canal compression. British Journal of Cancer , 86 S20 - S20.

Hoskin, PJ; Morgan, DAL; Robinson, M; (2002) Erythropoetin supplementation for radical radiotherapy in head and neck cancer: an interim analysis of a randomized phase III trial. In: Radiotherapy And Oncology. (pp. 83 - ?).

Howard, TT; Lingerfelt, BM; Purnell, BL; Scott, AE; Price, CA; Townes, HM; ... Lee, M; + view all (2002) Novel furano analogues of duocarmycin C1 and C2: Design, synthesis, and biological evaluation of seco-iso- cyclopropylfurano[2,3-e]indoline (seco-iso-CFI) and seco- cyclopropyltetrahydrofurano[2,3-f]quinoline (seco-CFQ) analogues. Bioorganic and Medicinal Chemistry , 10 (9) 2941 - 2952.

Howard, TT; Lingerfelt, BM; Purnell, BL; Scott, AE; Price, CA; Townes, HM; ... Lee, M; + view all (2002) Novel furano analogues of duocarmycin C1 and C2: Design, synthesis, and biological evaluation of seco-iso-cyclopropylfurano[2,3-e]indoline (seco-iso-CFI) and seco-cyclopropyltetrahydrofurano[2,3-f]quinoline (seco-CFQ) analogues. BIOORGAN MED CHEM , 10 (9) 2941 - 2952.

Hughes, A; Calvert, P; Azzabi, A; Plummer, R; Johnson, R; Rusthoven, J; ... Calvert, H; + view all (2002) Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J CLIN ONCOL , 20 (16) 3533 - 3544. 10.1200/JCO.2002.10.073.

J

Janinis, J; McTiernan, A; Driver, D; Mitchell, C; Cassoni, AM; Pringle, J; ... London Bone and Soft Tissue Tumour,; + view all (2002) A pilot study of short-course intensive multiagent chemotherapy in metastatic and axial skeletal osteosarcoma. ANN ONCOL , 13 (12) 1935 - 1944. 10.1093/annonc/mdf338.

Jones, B; Aird, E; Colyer, H; Dobbs, J; Harris, R; Hoskin, P; ... West, C; + view all (2002) United Kingdom Radiation Oncology 1 conference (UKRO 1): Accuracy and uncertainty in radiotherapy. British Journal of Radiology , 75 (892) 297 - 306.

Judson, I; Leahy, M; Whelan, JS; Lorigan, P; Verrill, M; Grimer, R; Robinson, M; (2002) A guideline for the management of gastrointestinal stromal tumour (GIST). Sarcoma , 6 83 - 87. Gold open access

K

Kiakos, K; Howard, TT; Lee, M; Hartley, JA; McHugh, PJ; (2002) Saccharomyces cerevisiae RAD5 influences the excision repair of DNA minor groove adducts. J BIOL CHEM , 277 (46) 44576 - 44581. 10.1074/jbc.M208169200. Gold open access

Kirkby, N; Faraday, DBF; Short, S; C, W; M, J; M C, B; N, G; (2002) Mathematical modelling to develop a novel radiotherapy schedule for high grade brain tumours, based on phase distribution of low-dose hypersensitivity in human glioma cell lines. In: Proc 21st Annual ESTRO meeting, Prague 2002.

Koch, SSC; Thoresen, LH; Tikhe, JG; Maegley, KA; Almassy, RJ; Li, JK; ... Hostomsky, Z; + view all (2002) Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis, and X-ray cocrystal structure. J MED CHEM , 45 (23) 4961 - 4974. 10.1021/jm02059n.

Kularatne, BY; Lorigan, P; Browne, S; Suvarna, SK; Smith, NO; Lawry, J; (2002) Monitoring tumour cells in the peripheral blood of small cell lung cancer patients. CYTOMETRY , 50 (3) 160 - 167. 10.1002/cyto.10071.

L

Lee, SM; James, LE; Mohamed-Ali, V; Boschoff, C; Snee, M; Brock, C; ... Prendiville, J; + view all (2002) A phase II study of carboplatin/etoposide with thalidomide in small cell lung cancer (SCLC). In: (Proceedings) Oral presentation. 2002 ASCO Annual Meeting/38th Annual Meeting, Orlando, FL.. (pp. 1251 - ?). Proceedings of the American Society of Clinical Oncology

Lee, YC; Boehm, MK; Chester, KA; Begent, RHJ; Perkins, SJ; (2002) Reversible dimer formation and stability of the anti-tumour single-chain Fv antibody MFE-23 by neutron scattering, analytical ultracentrifugation, and NMR and FT-IR spectroscopy. J MOL BIOL , 320 (1) 107 - 127. 10.1016/S0022-2836(02)00403-5.

Leonard, P; Seymour, MT; James, R; Hochhauser, D; Ledermann, JA; (2002) Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer. BRIT J CANCER , 87 (11) 1216 - 1220. 10.1038/sj.bjc.6606641.

M

Madsen, E; Summerville, K; Price, C; Toth, J; Hudson, S; Kiakos, K; ... Lee, M; + view all (2002) Molecular recognition of DNA sequence-specific alkylation by conjugates of hairpin polyamide-duocarmycin analogs. ABSTR PAP AM CHEM S , 223 A106 - A106.

Makris, A; Burcombe, RJ; Wilson, GD; Richman, PI; Allen, S; Wright, D; Pittam, M; (2002) Comparison of clinical, radiological and pathological assessment of response to neoadjuvant chemotherapy for primary breast cancer. European Journal of Cancer , 38 268 - ?.

Mayer, A; Spencer, DIR; Tolner, B; Purdy, D; Begent, RHJ; Chester, K; (2002) A recombinant fusion protein with potentially reduced immunogenicity for ADEPT. British Journal of Cancer , 86 S117 - S117.

Mayer, A; Spencer, DIR; Tolner, B; Purdy, D; Begent, RHJ; Chester, K; (2002) A recombinant fusion protein with potentially reduced immunogenicity for ADEPT. BRIT J CANCER , 86 S117 - S117.

McHugh, PJ; Kiakos, K; Hartley, JA; Lee, M; (2002) The Rad6 pathway is involved in the nucleotide excision repair of DNA minor groove adducts. In: Proceedings of the American Association of Cancer Research. (pp. 5103 - ?).

N

Nehls, O; Klump, B; Arkenau, HT; Hass, HG; Greschniok, A; Gregor, M; Porschen, R; (2002) Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial. Br J Cancer , 87 (7) 702 - 704. 10.1038/sj.bjc.6600543.

Nicholson, PW; Harland, SJ; (2002) Survival prospects after screen-detection of prostate cancer. BJU INT , 90 (7) 686 - 693. 10.1046/j.1464-4096.2002.03005.x.

Niyikiza, C; Baker, SD; Seitz, DE; Walling, JM; Nelson, K; Rusthoven, JJ; ... Allen, RH; + view all (2002) Homocysteine and methylmalonic acid: Markers to predict and avoid toxicity from pemetrexed therapy. MOL CANCER THER , 1 (7) 545 - 552.

Niyikiza, C; Hanauske, AR; Rusthoven, JJ; Calvert, AH; Allen, R; Paoletti, P; Bunn, PA; (2002) Pemetrexed safety and dosing strategy. SEMIN ONCOL , 29 (6) 24 - 29. 10.1053/sonc.2002.37465.

O

O'Hare, CC; Mack, D; Tandon, M; Sharma, SK; Lown, JW; Kopka, ML; ... Hartley, JA; + view all (2002) DNA sequence recognition in the minor groove by crosslinked polyamides: The effect of N-terminal head group and linker length on binding affinity and specificity. P NATL ACAD SCI USA , 99 (1) 72 - 77.

Okkenhaug, K; Bilancio, A; Farjot, G; Priddle, H; Sancho, S; Peskett, E; ... Vanhaesebroeck, B; + view all (2002) Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science , 297 (5583) 1031 - 1034. 10.1126/science.1073560.

P

Parmar, MKB; Adams, M; Balestrino, M; Bertelsen, K; Bonazzi, C; Calvert, H; ... ICON Grp,; + view all (2002) Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. LANCET , 360 (9332) 505 - 515.

Paul, MJ; Summers, Y; Calvert, AH; Rustin, G; Brampton, MH; Thatcher, N; Middleton, MR; (2002) Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. MELANOMA RES , 12 (2) 175 - 178.

Pedley, RB; El-Emir, E; Flynn, AA; Boxer, GM; Dearling, J; Raleigh, JA; ... Begent, RHJ; + view all (2002) Synergy between vascular targeting agents and antibody-directed therapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS , 54 (5) 1524 - 1531.

Pedley, RB; Sharma, SK; Chester, KA; (2002) Antibody-directed Enzyme Prodrug Therapy. In: Suicide Gene Therapy: Methods and Protocols for Cancer. Humana Press

Peters, GJ; Backus, HHJ; Freemantle, S; van Triest, B; Codacci-Pisanelli, G; van der Wilt, CL; ... Pinedo, HM; + view all (2002) Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE , 1587 (2-3) 194 - 205.

Petrie, IA; Flynn, AA; Pedley, RB; Green, AJ; El-Emir, E; Dearling, J; ... Boden, RABRHJ; + view all (2002) The spatial accuracy of 3D reconstructed radioluminographs on serial tissue sections and the resultant absorbed dose estimates. Physics in Medicine and Biology , 47 3651 - 3661.

Petrie, IA; Flynn, AA; Pedley, RB; Green, AJ; El-Emir, E; Dearling, JLJ; ... Begent, RHJ; + view all (2002) Spatial accuracy of 3D reconstructed radioluminographs of serial tissue sections and resultant absorbed dose estimates. PHYS MED BIOL , 47 (20) 3651 - 3661.

Plummer, R; Ghielmini, M; Calvert, P; Voi, M; Renard, J; Gallant, G; ... Sessa, C; + view all (2002) Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies. CLIN CANCER RES , 8 (9) 2788 - 2797.

Purnell, B; Howard, T; Lingerfelt, B; McNulty, L; Handl, H; Summerville, K; ... Bowen, P; + view all (2002) Novel seco-iso-CFI and seco-CFQ analogs of the duocarmycins: Design, synthesis and biological evaluation. ABSTR PAP AM CHEM S , 223 B133 - B133.

Purnell, B; Lingerfelt, B; Scott, A; Summerville, K; Hudson, S; Kiakos, K; ... Lee, M; + view all (2002) Novel (S)-(+)- and (R)-(-)-seco-iso-CFI analogs of duocarmycin C2. ABSTR PAP AM CHEM S , 223 B133 - B133.

R

Rojas, A; Saunders, MI; (2002) Addition of chemotherapy to altered fractionation schedules in non-small cell lung cancer. In: Kogelnik, HD and Lukas, P and Sedlmayer, F, (eds.) Progress in Radio-oncology VII. (437 - 445). Monduzzi

Rojas, A; Saunders, MI; (2002) ARCON in clinical radiotherapy. In: Kogelnik, HD and Lukas, P and Sedlmayer, F, (eds.) Progress in Radio-oncology. (89 - 98).

Rudd, RM; Gower, NH; James, LE; Gregory, W; Eisen, T; Lee, SM; et, A; (2002) A phase III randomised comparison of gemcitabine/carboplatin with mitomycin/ifosfamide/cisplatin in advanced non-small cell lung cancer. In: (Proceedings) Oral presentation. 2002 Annual ASCO Meeting/38th Annual Meeting, Orlando, FL.. (pp. 1164 - ?). Proceedings of the American Society of Clinical Oncology

S

Saunders, MI; (2002) Chart and chemotherapy. Clinical Oncology , 14 (4) 331 - 332.

Saunders, MI; Rojas, A; Lyn, BE; Wilson, E; Phillips, H; (2002) Dose-escalation with CHARTWEL (Continuous Hyperfractionated Accelerated Radiotherapy Week-End Less) combined with neo- adjuvant chemotherapy in the treatment of locally advanced non- small cell lung cancer. Clinical Oncology , 14 (5) 352 - 360.

Schellens, JHM; Heinrich, B; Lehnert, M; Gore, ME; Kaye, SB; Dombernowsky, P; ... Hanauske, AR; + view all (2002) Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies. INVEST NEW DRUG , 20 (1) 83 - 93.

Sharma, SK; Pedley, RB; Bhatia, J; Irwin, HL; El-Emir, E; Boxer, GM; ... R, HJ; + view all (2002) Antibody-directed enzyme prodrug therapy (ADEPT): comparison in two colorectal carcinoma xenografts. In: (Proceedings) proceedings AmericanAssociation for Cancer Research. (pp. 943 - ?).

Short, SC; Harney, J; Dopson, F; Saunders, MI; (2002) The effects of low-dose fractionated radiation on sarcomas- experimental and clinical data. British Journal of Cancer , 86 S56 - S57.

Sibtain, A; Hill, S; Goodchild, K; Shah, N; Saunders, M; Hoskin, PJ; (2002) The modification of human tumour blood flow using pentoxifylline, nicotinamide and carbogen. Radiotherapy And Oncology , 62 (1) 69 - 76.

Sibtain, A; Wilson, GD; Hoskin, PJ; (2002) Hypoxia in bladder cancer: Validation of intrinsic markers with pimonidazole and their influence on clinical outcome after accelerated radiotherapy with carbogen and nicotinamide. British Journal of Cancer , 86 S28 - S29.

Sierens, J; Hartley, JA; Campbell, MJ; Leathem, AJC; Woodside, JV; (2002) In vitro isoflavone supplementation reduces hydrogen peroxide-induced DNA damage in sperm. TERATOGEN CARCIN MUT , 22 (3) 227 - 234. 10.1002/tcm.10015.

Simpson, AB; Calvert, PM; Sludden, JA; Boddy, AV; Griffin, MJ; Schatzlein, A; ... Twelves, CJ; + view all (2002) Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules. ANN ONCOL , 13 (3) 399 - 402. 10.1093/annonc/mdf041.

Southworth, R; Dearling, J; Medina, R; Flynn, A; Pedley, RBAG; P,; (2002) 18FDG and 14C DG6P accumulation differ in the isolated heart: an autoradiographic study. In: J Mol. Cell. Cardiol. (pp. 59 - ?).

Southworth, R; Dearling, JLJ; Medina, RA; Flynn, AA; Pedley, RB; Garlick, PB; (2002) Dissociation of glucose tracer uptake and glucose transporter distribution in the regionally ischaemic isolated rat heart: application of a new autoradiographic technique. EUR J NUCL MED MOL I , 29 (10) 1334 - 1341. 10.1007/s00259-002-0922-2.

Spalding, DRC; Hochhauser, D; Hartley, J; Davidson, B; (2002) Heterogeneity of response to chemotherapy in liver tumours evaluated by the comet assay in an isolated perfused human liver. British Journal Of Surgery , 89 50 - 50.

Spanswick, VJ; Craddock, C; Sekhar, M; Mahendra, P; Shankaranarayana, P; Hughes, RG; ... Hartley, JA; + view all (2002) Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. BLOOD , 100 (1) 224 - 229. Green open access
file

Spanswick, VJ; Craddock, C; Sekhar, M; Mahendra, P; Shankaranarayana, P; Hughes, RG; ... Hartley, JA; + view all (2002) Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. Blood , 100 (1) 224 - 229.

Spencer, DI; Robson, L; Purdy, D; Whitelegg, NR; Michael, NP; Bhatia, J; ... Chester, KA; + view all (2002) A strategy for mapping and neutralizing conformational immunogenic sites on protein therapeutics. Proteomics , 2 (3) 271 - 279.

Spencer, DIR; Robson, L; Purdy, D; Whitelegg, NR; Michael, NP; Bhatia, J; ... Chester, KA; + view all (2002) A strategy for mapping and neutralizing conformational immunogenic sites on protein therapeutics. PROTEOMICS , 2 (3) 271 - 279.

Szekely, Z; Kosakowska-Cholody, T; Hartley, JA; Michejda, CJ; (2002) Coupling minor groove binders with intercalators, an attempt to design chemical gene knockout agents. In: Proceedings of the American Association of Cancer Research. (pp. 2428 - ?).

T

Tchilian, EZ; Dawes, R; Ramaley, PA; Whitworth, JA; Yuldasheva, N; Wells, RS; ... Beverley, PCL; + view all (2002) A CD45 polymorphism associated with abnormal splicing is absent in African populations. IMMUNOGENETICS , 53 (10-11) 980 - 983. 10.1007/s00251-001-0410-z.

Thomas, HD; Porter, DJ; Bartelink, I; Nobbs, JR; Cole, M; Elliott, S; ... Boddy, AV; + view all (2002) Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide. BRIT J CLIN PHARMACO , 53 (1) 83 - 91.

Thomas, R; Makris, A; Bloomfield, D; Godward, S; Moody, M; (2002) Empowering patients to make informed treatment decisions based on tolerability, quality of life patient preference. A comparison of letrozole and anastrazole in a multicentre, randomised, single-blind cross over study. European Journal of Cancer , 38 171 - ?.

Toth, JL; Price, CA; Madsen, EC; Handl, HL; Hudson, SJ; Hubbard, RB; ... Lee, M; + view all (2002) Sequence selective recognition of DNA by hairpin conjugates of a racemic seco-cyclopropaneindoline-2-benzofurancarboxamide and polyamides. BIOORG MED CHEM LETT , 12 (16) 2245 - 2248.

Toth, JL; Price, CA; Madsen, EC; Handl, HL; Hudson, SJ; Hubbard, RB; ... Lee, M; + view all (2002) Sequence selective recognition of DNA by hairpin conjugates of a racemic seco-cyclopropaneindoline-2-benzofurancarboxamide and polyamides. Bioorg Med Chem Lett , 12 (16) 2245 - 2248.

Trent, S; Kong, A; Short, SC; Traish, D; Ashley, S; Dowe, A; ... Brada, M; + view all (2002) Temozolomide as second-line chemotherapy for relapsed gliomas. Journal of Neuro-Oncology , 57 (3) 247 - 251.

U

UCL, 22AR; (2002) Achievements: UCL's academics conducted pioneering work at the forefront of their disciplines during this year. 12 - 13.

UCL, PS; (2002) Thalidomide to be used in cancer fight. 44 - ?.

V

Vassileva, V; Millar, A; Briollais, L; Chapman, W; Bapat, B; (2002) Genes involved in DNA repair are mutational targets in endometrial cancers with microsatellite instability. CANCER RES , 62 (14) 4095 - 4099.

Venables, K; Winfield, E; Aird, E; Hoskin, PJ; (2002) Three-dimensional distribution of radiation within the breast: an intercomparison of departments participating in the START trial of breast radiotherapy fractionation. International Journal of Radiation Oncology Biology Physics , 55 271 - 279.

W

Whelan, JS; Burcombe, RJ; Janinis, J; Baldelli, AM; Cassoni, AM; (2002) A systematic review of the role of pulmonary irradiation in the management of primary bone tumours. Ann Oncol , 13 (1) 23 - 30.

Winfield, E; Deighton, A; Venables, K; Hoskin, PJ; Aird, EGA; (2002) Survey of UK breast radiotherapy techniques: Background prior to the introduction of the quality assurance programme for the START (Standardisation of Radiotherapy) Trial in breast cancer. Clinical Oncology , 14 (4) 267 - 271.

Wong, WL; Campbell, H; Saunders, M; (2002) Positron emission tomography (PET) - Evaluation of 'indeterminate pulmonary lesions'. Clinical Oncology , 14 (2) 123 - 128.

Z

Zehnder, D; Bland, R; Chana, RS; Wheeler, DC; Howie, AJ; Williams, MC; ... Hewison, M; + view all (2002) Synthesis of 1,25-dihydroxyvitamin D-3 by human endothelial cells is regulated by inflammatory cytokines: A novel autocrine determinant of vascular cell adhesion. J AM SOC NEPHROL , 13 (3) ? - ?.

Zhang, J; Vanhaesebroeck, B; Rittenhouse, SE; (2002) Human platelets contain p110 delta phosphoinositide 3-kinase. BIOCHEM BIOPH RES CO , 296 (1) 178 - 181.

Zhang, J; Vanhaesebroeck, B; Rittenhouse, SE; (2002) Human platelets contain p110 delta phosphoinositide 3-kinase. BIOCHEM BIOPH RES CO , 296 (1) 178 - 181.

This list was generated on Sun Jul 27 03:57:14 2014 BST.